Gilead Sciences target raised to USD 158.00: stock pre-market at EUR 131.46, plus 0.19 percent
Published on 10/09/2026 at 08:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- Truist Financial raised its Gilead target to USD 158.00 on October 7, 2026.
- Gilead Sciences stock was at EUR 131.46 pre-market at 8:11 a.m. CEST.
- The price was up 0.19 percent versus the Lang & Schwarz prior close.
On October 7, 2026, MarketBeat reported that Truist Financial raised its price target for Gilead Sciences to USD 158.00 from USD 150.00 and maintained a buy rating.
Gilead Sciences stock was at EUR 131.46 in pre-market trading at Lang & Schwarz at 8:11 a.m. CEST on October 9, 2026. That was up EUR 0.25, or 0.19 percent, versus the Lang & Schwarz prior close of EUR 131.21 on October 8, 2026. The bid was EUR 131.10 and the ask was EUR 131.82. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Gilead Sciences stock.
What matters today
The next trading date in this report is October 9, 2026. The ask of EUR 131.82 is 0.27 percent above the pre-market price. Truist Financial’s most recent target was USD 158.00, according to the October 7, 2026 report.
MarketBeat also reported a consensus rating of Moderate Buy and an average analyst target of USD 159.15 for Gilead Sciences. Its report said 23 analysts had buy ratings and six had hold ratings.
Market context: Market report S&P 500.
